A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Phase 3 Unknown 220 enrolled Jiangsu Hansoh Pharmaceutical Co., Ltd.

RandomizedParallel-groupOpen-labelTreatment

Summary

To assess the efficacy and safety of Almonertinib versus platinum-based chemotherapy as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutation.

Timeline

Start: 2021-07-15
Primary completion: 2023-10-04
Completion: 2024-09-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Almonertinib	Small molecule	165 mg	Oral
Comparator	Carboplatin	Small molecule	5 unknown	—
Comparator	Cisplatin	Other / unclassified	75 mg/m2	—
Comparator	Pemetrexed	Small molecule	500 mg/m2	—

A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Summary

Timeline

Drugs

Indications